Literature DB >> 10572087

A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF.

M E Hoatlin1, Y Zhi, H Ball, K Silvey, A Melnick, S Stone, S Arai, N Hawe, G Owen, A Zelent, J D Licht.   

Abstract

Fanconi anemia (FA) is an autosomal recessive cancer susceptibility syndrome. The phenotype includes developmental defects, bone marrow failure, and cell cycle abnormalities. At least eight complementation groups (A-H) exist, and although three of the corresponding complementation group genes have been cloned, they lack recognizable motifs, and their functions are unknown. We have isolated a binding partner for the Fanconi anemia group C protein (FANCC) by yeast two-hybrid screening. We show that the novel gene, FAZF, encodes a 486 amino acid protein containing a conserved amino terminal BTB/POZ protein interaction domain and three C-terminal Krüppel-like zinc fingers. FAZF is homologous to the promyelocytic leukemia zinc finger (PLZF) protein, which has been shown to act as a transcriptional repressor by recruitment of nuclear corepressors (N-CoR, Sin3, and HDAC1 complex). Consistent with a role in FA, BTB/POZ-containing proteins have been implicated in oncogenesis, limb morphogenesis, hematopoiesis, and proliferation. We show that FAZF is a transcriptional repressor that is able to bind to the same DNA target sequences as PLZF. Our data suggest that the FAZF/FANCC interaction maps to a region of FANCC deleted in FA patients with a severe disease phenotype. We also show that FAZF and wild-type FANCC can colocalize in nuclear foci, whereas a patient-derived mutant FANCC that is compromised for nuclear localization cannot. These results suggest that the function of FANCC may be linked to a transcriptional repression pathway involved in chromatin remodeling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10572087

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

Review 1.  All in the family: the BTB/POZ, KRAB, and SCAN domains.

Authors:  T Collins; J R Stone; A J Williams
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions.

Authors:  A Melnick; K F Ahmad; S Arai; A Polinger; H Ball; K L Borden; G W Carlile; G G Prive; J D Licht
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 3.  Fanconi anaemia.

Authors:  M D Tischkowitz; S V Hodgson
Journal:  J Med Genet       Date:  2003-01       Impact factor: 6.318

Review 4.  POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function.

Authors:  Sung-Uk Lee; Takahiro Maeda
Journal:  Immunol Rev       Date:  2012-05       Impact factor: 12.988

5.  ZBTB32 Restricts the Duration of Memory B Cell Recall Responses.

Authors:  Arijita Jash; Yinan Wang; Florian J Weisel; Christopher D Scharer; Jeremy M Boss; Mark J Shlomchik; Deepta Bhattacharya
Journal:  J Immunol       Date:  2016-06-29       Impact factor: 5.422

Review 6.  The BTB-ZF transcription factors.

Authors:  Owen M Siggs; Bruce Beutler
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

7.  The BTB-ZF family of transcription factors: key regulators of lineage commitment and effector function development in the immune system.

Authors:  Aimee M Beaulieu; Derek B Sant'Angelo
Journal:  J Immunol       Date:  2011-09-15       Impact factor: 5.422

8.  The Fanconi anemia protein FANCC binds to and facilitates the activation of STAT1 by gamma interferon and hematopoietic growth factors.

Authors:  Q Pang; S Fagerlie; T A Christianson; W Keeble; G Faulkner; J Diaz; R K Rathbun; G C Bagby
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

9.  Fanconi anemia FANCG protein in mitigating radiation- and enzyme-induced DNA double-strand breaks by homologous recombination in vertebrate cells.

Authors:  Kazuhiko Yamamoto; Masamichi Ishiai; Nobuko Matsushita; Hiroshi Arakawa; Jane E Lamerdin; Jean-Marie Buerstedde; Mitsune Tanimoto; Mine Harada; Larry H Thompson; Minoru Takata
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

Review 10.  Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy.

Authors:  Paul R Andreassen; Keqin Ren
Journal:  Curr Cancer Drug Targets       Date:  2009-02       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.